You can help researchers improve public health by volunteering for NIAID clinical studies related to biodefense.
Emerging infectious diseases can be defined as infectious diseases that have newly appeared in a population or have existed but are rapidly increasing in incidence or geographic range, or that are caused by one of the NIAID Category A, B, or C priority pathogens.
NIAID’s Emerging Infectious Diseases/Pathogens category includes Biodefense Research and Additional Emerging Infectious Diseases/Pathogens.
NIAID’s pathogen priority list is periodically reviewed and is subject to revision in conjunction with our federal partners, including the U.S. Department of Homeland Security, which determines threat assessments, and the Centers for Disease Control and Prevention, which is responsible for responding to emerging pathogen threats in the United States.
Category A pathogens are those organisms/biological agents that pose the highest risk to national security and public health because they
Category B pathogens are the second highest priority organisms/biological agents. They
Category C pathogens are the third highest priority and include emerging pathogens that could be engineered for mass dissemination in the future because of
Immunology studies that advance our understanding of host defenses applicable to the biodefense effort, for example
back to top
Notes:* This list was created for the purpose of extramural and intramural program management within NIAID’s biodefense/EID mission and does not represent the complete scope of biodefense and emerging infectious disease.** HIV/AIDS is excluded.
Last Updated February 25, 2015